Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as a unknown/unknown for oral use. It treats idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adults.

GNH USA supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nintedanib is used to target fibrotic lung disease pathways, primarily in progressive interstitial lung conditions.

- Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function. - Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity. - Progressive fibrosing interstitial lung disease: delays functional deterioration in patients with other fibrotic ILDs.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Elevated liver enzymes: potential indication of hepatic injury. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular events: includes myocardial infarction or stroke. - Severe infections: opportunistic or serious bacterial infections. - Gastrointestinal perforation: rare but life‑threatening condition.

When prescribing Nintedanib, clinicians should consider several safety measures.

- Renal function: assess and monitor in patients with impaired kidney function. - Hepatic function: obtain baseline liver tests and monitor periodically. - Bleeding risk: avoid concomitant use of strong anticoagulants unless medically necessary. - Pregnancy: avoid use during pregnancy; limited data, potential fetal risk. - Drug interactions: review all concomitant medications for CYP3A4 or P‑gp involvement. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines through metabolic pathways and hemostatic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive hemorrhagic potential.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑glycoprotein inhibitors (e.g., verapamil): modest increase in plasma levels. - NSAIDs: monitor for gastrointestinal bleeding.